Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer

Cancer

Volumn 117, Issue 18, 2011, Pages 4175-4183

  Slattery, Martha L ^a   Lundgreen, Abbie ^a   Herrick, Jennifer S ^a   Wolff, Roger K ^a   Caan, Bette J ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

Author keywords

bone morphogenetic protein; colon cancer; prognosis; rectal cancer; Runt related transcription factors; smooth muscle actin mothers against decapentaplegic homolog; survival; transforming growth factor

Indexed keywords

BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN 2; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN 3; GROWTH DIFFERENTIATION FACTOR 10; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOGENIN; PROCOLLAGEN C PROTEINASE; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BONE MORPHOGENETIC PROTEIN 1 GENE; BONE MORPHOGENETIC PROTEIN 2 GENE; BONE MORPHOGENETIC PROTEIN 4 GENE; BONE MORPHOGENETIC PROTEIN GENE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A GENE; BONE MORPHOGENETIC PROTEIN RECEPTOR 1B GENE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2 GENE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN 2 GENE; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN 3 GENE; EUKARYOTIC TRANSLATION INITIATION FACTOR 4E GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GROWTH DIFFERENTIATION FACTOR 10 GENE; HUMAN; INITIATION FACTOR 4E GENE; MAJOR CLINICAL STUDY; MALE; MITOGEN ACTIVATED PROTEIN KINASE 1 GENE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; RECTUM CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMAD GENE; SMAD1 GENE; SMAD2 GENE; SMAD3 GENE; SMAD4 GENE; SMAD7 GENE; TRANSCRIPTION FACTOR RUNX1 GENE; TRANSCRIPTION FACTOR RUNX2 GENE; TRANSCRIPTION FACTOR RUNX3 GENE; TRANSFORMING GROWTH FACTOR BETA GENE;

AGED; COLONIC NEOPLASMS; FEMALE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECTAL NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 80052505918     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26018     Document Type: Article

References (36)

1. Gordon KJ, Blobe GC,. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008; 1782: 197-228.
2. Piccirillo SG, Vescovi AL,. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc. 2006; 5: 59-81.
3. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006; 444: 761-765. (Pubitemid 44949605)
4. Blyth K, Cameron ER, Neil JC,. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005; 5: 376-387. (Pubitemid 40637829)
5. Lee KS, Hong SH, Bae SC,. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 2002; 21: 7156-7163.
6. Cameron ER, Blyth K, Hanlon L, et al. The Runx genes as dominant oncogenes. Blood Cells Mol Dis. 2003; 30: 194-200. (Pubitemid 36539363)
7. Ito Y, Osato M, Ito K,. RUNX and cancer. Ann Acad Med Singapore. 2003; 32 (5 suppl): S6-S7.
8. Ge C, Xiao G, Jiang D, et al. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem. 2009; 284: 32533-32543.
9. Guo H, Zhang HY, Wang SL, Ye L, Yang GH, Bu H,. Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma. Chin Med J (Engl). 2007; 120: 515-521. (Pubitemid 46510765)
10. Javelaud D, Mauviel A,. Smad signal transduction. Interplays between the Smad and Map kinase signaling pathways. Proteins Cell Regul. 2006; 5: 317-334.
11. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A,. Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev. 2001; 10: 663-666. (Pubitemid 32703201)
12. Rajasekhar VK, Holland EC,. Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene. 2004; 23: 3248-3264. (Pubitemid 38638836)
13. Slattery ML, Herrick JS, Lundgreen A, Wolff RK,. Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prevent. 2011; 20: 57-69.
14. Slattery ML, Herrick J, Curtin K, et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res. 2010; 70: 1479-1485.
15. Slattery ML, Lundgreen A, Herrick SJ, Caan BJ, Potter JD, Wolff RK,. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1, and eIF4E and risk of colon and rectal cancer: additional support for a TGF-β signaling pathway [published online ahead of print November 28, 2010]. Carcinogenesis. 2010.
16. Slattery ML, Potter JD, Duncan DM, Berry TD,. Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int J Cancer. 1997; 73: 670-677. (Pubitemid 127483062)
17. Slattery ML, Caan BJ, Benson J, Murtaugh M,. Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr Cancer. 2003; 46: 166-171. (Pubitemid 37504976)
18. Samowitz WS, Curtin K, Ma KN, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer. 2002; 99: 597-602. (Pubitemid 34461615)
19. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst. 2000; 92: 1831-1836.
20. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML,. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev. 2000; 9: 1193-1197.
21. Slattery ML, Curtin K, Sweeney C, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007; 120: 656-663. (Pubitemid 44969038)
22. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev. 2001; 10: 917-923. (Pubitemid 32844897)
23. Zha Y, Leung KH, Lo KK, et al. TGFB1 as a susceptibility gene for high myopia: a replication study with new findings. Arch Ophthalmol. 2009; 127: 541-548.
24. Xu Y, Pasche B,. TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007; 16 (spec no. 1): R14-R20. (Pubitemid 47241839)
25. Saltzman BS, Yamamoto JF, Decker R, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia. Cancer Res. 2008; 68: 1236-1244. (Pubitemid 351272244)
26. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M,. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009; 1796: 315-331.
27. Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, Peeva K,. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis. 2010; 25: 591-599.
28. Hong S, Lee HJ, Kim SJ, Hahm KB,. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-beta signaling. World J Gastroenterol. 2010; 16: 2080-2093.
29. Bellam N, Pasche B,. Tgf-beta signaling alterations and colon cancer. Cancer Treat Res. 2010; 155: 85-103.
30. Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK,. Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer. Int J Cancer. In press.
31. Chen LS, Hutter CM, Potter JD, et al. Insights into colon cancer etiology via a regularized approach to gene set analysis of GWAS data. Am J Hum Genet. 2010; 86: 860-871.
32. Forsti A, Li X, Wagner K, et al. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression. Genes Chromosomes Cancer. 2010; 49: 270-281.
33. Tsamandas AC, Kardamakis D, Ravazoula P, et al. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol. 2004; 180: 201-208. (Pubitemid 38461544)
34. Isaksson-Mettavainio M, Palmqvist R, Forssell J, Stenling R, Oberg A,. SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res. 2006; 26 (1B): 507-510. (Pubitemid 43206008)
35. Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M,. Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J. 2003; 9: 302-312.
36. Boulay JL, Mild G, Lowy A, et al. SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer. 2003; 104: 446-449. (Pubitemid 36323914)